Abstract
Malaria is a devastating human parasitic disease that receives enhanced attention due to the emergence of resistance to traditional drugs. Thus, the search for new molecular targets is a major goal. PfAM1 is an aminopeptidase from Plasmodium falciparum, William H. Welch 1897, belonging to the M1 family of metalloproteases, which is a promising target of inhibitors to block the intra-erythrocytic stages of the parasite. Since its identification in 1998, many efforts have been done to validate PfAM1 as an appropriate target of antimalarials. The present work is a critical review of the main structural, functional and kinetic characteristics of PfAM1, as well as a summary of the effects of key inhibitors at molecular and cellular levels. The systematization of experimental results should contribute to a better understanding of the properties of PfAM1 as a target of antimalarials and promote research projects focused on the development of PfAM1 inhibitors.
Keywords: Antimalarials, growth inhibition, M1 family, metallo-aminopeptidases, Plasmodium falciparum, protease inhibitors.
Current Drug Targets
Title:Plasmodium falciparum M1-Aminopeptidase: A Promising Target for the Development of Antimalarials
Volume: 15 Issue: 12
Author(s): Jorge Gonzalez-Bacerio, Rafael Fando, Alberto del Monte-Martinez, Jean-Louis Charli and Maria de los A. Chávez
Affiliation:
Keywords: Antimalarials, growth inhibition, M1 family, metallo-aminopeptidases, Plasmodium falciparum, protease inhibitors.
Abstract: Malaria is a devastating human parasitic disease that receives enhanced attention due to the emergence of resistance to traditional drugs. Thus, the search for new molecular targets is a major goal. PfAM1 is an aminopeptidase from Plasmodium falciparum, William H. Welch 1897, belonging to the M1 family of metalloproteases, which is a promising target of inhibitors to block the intra-erythrocytic stages of the parasite. Since its identification in 1998, many efforts have been done to validate PfAM1 as an appropriate target of antimalarials. The present work is a critical review of the main structural, functional and kinetic characteristics of PfAM1, as well as a summary of the effects of key inhibitors at molecular and cellular levels. The systematization of experimental results should contribute to a better understanding of the properties of PfAM1 as a target of antimalarials and promote research projects focused on the development of PfAM1 inhibitors.
Export Options
About this article
Cite this article as:
Gonzalez-Bacerio Jorge, Fando Rafael, Monte-Martinez del Alberto, Charli Jean-Louis and Chávez de los A. Maria, Plasmodium falciparum M1-Aminopeptidase: A Promising Target for the Development of Antimalarials, Current Drug Targets 2014; 15 (12) . https://dx.doi.org/10.2174/1389450115666141024115641
DOI https://dx.doi.org/10.2174/1389450115666141024115641 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Approaches to Induce Neuroregeneration in Spinal Cord Injury: An Overview
Current Drug Discovery Technologies Purification and Characterization of Human Brain Serine Racemase Expressed in Moderately Halophilic Bacteria
Protein & Peptide Letters Targeting Transcription Factors for Cancer Therapy
Current Pharmaceutical Design NK Cells and HIV Infection: Lessons from other Viruses
Current Molecular Medicine A Novel Oromucosal Prolonged Release Mucoadhesive Suspension by One Step Spray Coagulation Method
Current Drug Delivery Recent Advances in the Synthesis of Sphingosine and Phytosphingosine, Molecules of Biological Significance
Current Organic Chemistry Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research The Role of the O-GlcNAc Modification in Regulating Eukaryotic Gene Expression
Current Signal Transduction Therapy Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews Dual Role of Heat Shock Proteins (HSPs) in Anti-Tumor Immunity
Current Molecular Medicine Bioremediation of Toxic Heavy Metals: A Patent Review
Recent Patents on Biotechnology Inflammation, Hyperinflammation & Cystic Fibrosis Lung Disease – A Paradigm Shift?
Current Respiratory Medicine Reviews Stevens Johnson Syndrome versus Jarisch Herxheimer Reaction in an HIV Positive Patient with Secondary Syphilis
Recent Patents on Inflammation & Allergy Drug Discovery Cancer Immunotherapy: Diverse Approaches and Obstacles
Current Pharmaceutical Design Editorial (Sulodexide, An Old Drug with Recent Renewed Interest)
Current Vascular Pharmacology MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD
Current Alzheimer Research Phytochemistry, Antinociceptive and Anti-inflammatory Actvities of Methanolic Leaves Extract of Lannea schimperi (Hoschst. Ex Rich) ENG.
Recent Patents on Biotechnology Progress Towards Liver and Lung-Directed Gene Therapy with Helper- Dependent Adenoviral Vectors
Current Gene Therapy Development Of Etofenamate-Loaded Semisolid Sln Dispersions And Evaluation Of Anti-Inflammatory Activity For Topical Application
Current Drug Delivery